India's Sun Pharma plans $1 billion local debt sale for loan takeout, sources say

• Sun Pharma will issue bonds with 2-, 3-, and 4-year maturities to replace part of a nearly $12 billion, 18-month bridge loan closed earlier this year for the Organon acquisition
• High US yields (10-year at highest since mid-2007) are driving Indian companies toward domestic debt markets, with bankers expecting record corporate issuances this year
• About $3 billion in rupee debt issuances are lined up as companies rush to lock in rates ahead of a potential Reserve Bank of India rate hike

Summary

Key Transaction Details:

India's Sun Pharmaceutical Industries is planning to raise approximately 100 billion rupees ($1.04 billion) through a rupee-denominated bond sale to partially refinance a bridge loan used to acquire U.S. healthcare firm Organon & Co. The company, India's largest drugmaker by market capitalization, previously secured an $12 billion, 18-month bridge loan syndication earlier this year for the Organon acquisition, which included participation from State Bank of India.

Debt Structure:

Sun Pharma will issue shorter-duration bonds with maturities of two, three, and four years. This move represents a shift from dollar-denominated to local currency funding.

Market Context:

The debt issuance reflects broader market trends driven by elevated U.S. borrowing costs. The 10-year U.S. Treasury yield is hovering at its highest level since mid-June 2007, making dollar funding more expensive and pushing companies toward domestic debt markets. Bankers expect Indian corporate debt issuances to reach record levels this year due to these dynamics.

Timing Considerations:

Indian companies are accelerating borrowing efforts to lock in rates ahead of a potential rate hike by the Reserve Bank of India. Approximately $3 billion worth of rupee debt issuances are scheduled over the coming days.

Market Implications:

This transaction highlights the growing preference for local currency financing among Indian corporates amid challenging global credit conditions. The shift demonstrates how rising U.S. yields are reshaping corporate funding strategies in emerging markets, particularly for large-scale M&A transactions.